Published in J Virol on April 01, 1999
The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol (2003) 4.23
Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog (2005) 3.59
Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev (2004) 3.39
Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol (2007) 2.64
APOBEC3G targets specific virus species. J Virol (2004) 1.78
Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J Virol (2007) 1.51
The multimerization of human immunodeficiency virus type I Vif protein: a requirement for Vif function in the viral life cycle. J Biol Chem (2000) 1.32
The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H. J Virol (2011) 1.26
Zinc binding to the HCCH motif of HIV-1 virion infectivity factor induces a conformational change that mediates protein-protein interactions. Proc Natl Acad Sci U S A (2006) 1.20
Amplification of a complete simian immunodeficiency virus genome from fecal RNA of a wild chimpanzee. J Virol (2003) 1.20
The SOCS-box of HIV-1 Vif interacts with ElonginBC by induced-folding to recruit its Cul5-containing ubiquitin ligase complex. PLoS Pathog (2010) 1.15
Crystal structure of the DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-binding domain. Structure (2013) 1.13
Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity. J Virol (2010) 1.09
Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity. Proteins (2007) 1.04
Implication of the lymphocyte-specific nuclear body protein Sp140 in an innate response to human immunodeficiency virus type 1. J Virol (2002) 1.03
Advances in the structural understanding of Vif proteins. Curr HIV Res (2008) 1.03
Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity. J Virol (2010) 0.98
Multifaceted counter-APOBEC3G mechanisms employed by HIV-1 Vif. J Mol Biol (2011) 0.93
Core binding factor beta plays a critical role by facilitating the assembly of the Vif-cullin 5 E3 ubiquitin ligase. J Virol (2014) 0.92
Intravirion processing of the human immunodeficiency virus type 1 Vif protein by the viral protease may be correlated with Vif function. J Virol (2002) 0.91
Functional analysis of Vif protein shows less restriction of human immunodeficiency virus type 2 by APOBEC3G. J Virol (2005) 0.89
Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS. Future Virol (2009) 0.89
The inhibition of assembly of HIV-1 virus-like particles by 3-O-(3',3'-dimethylsuccinyl) betulinic acid (DSB) is counteracted by Vif and requires its Zinc-binding domain. Virol J (2008) 0.88
ADAR1 is a novel multi targeted anti-HIV-1 cellular protein. Virology (2011) 0.86
Molecular insight into the conformational dynamics of the Elongin BC complex and its interaction with HIV-1 Vif. J Mol Biol (2010) 0.86
Unexpected diversity of cellular immune responses against Nef and Vif in HIV-1-infected patients who spontaneously control viral replication. PLoS One (2010) 0.82
Improvement in efficacy of DNA vaccine encoding HIV-1 Vif by LIGHT gene adjuvant. Viral Immunol (2013) 0.79
Insight into the HIV-1 Vif SOCS-box-ElonginBC interaction. Open Biol (2013) 0.77
Codon pairs of the HIV-1 vif gene correlate with CD4+ T cell count. BMC Infect Dis (2013) 0.76
Maintenance or emergence of chronic phase secondary cytotoxic T lymphocyte responses after loss of acute phase immunodominant responses does not protect SIV-infected rhesus macaques from disease progression. J Biomed Biotechnol (2010) 0.75
Functional dissection of the HIV-1 Rev trans-activator--derivation of a trans-dominant repressor of Rev function. Cell (1989) 7.46
Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol (1993) 6.11
Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol (1992) 5.85
Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat Med (1998) 3.84
HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science (1998) 3.28
The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J Virol (1996) 3.22
Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles. J Virol (1993) 3.01
HIV-1 auxiliary proteins: making connections in a dying cell. Cell (1998) 2.68
Human immunodeficiency virus type 1 Vif- mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity. J Virol (1995) 2.45
Conservation of amino-acid sequence motifs in lentivirus Vif proteins. Virus Genes (1992) 2.40
The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells. J Virol (1997) 2.39
Subcellular localization of the Vif protein of human immunodeficiency virus type 1. J Virol (1994) 2.35
Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes. J Virol (1995) 2.35
Role of Vif in human immunodeficiency virus type 1 reverse transcription. J Virol (1996) 2.35
Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein. J Virol (1996) 2.30
The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures. J Virol (1995) 2.25
Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J Virol (1996) 1.76
Characterization of human immunodeficiency virus type 1 Vif particle incorporation. J Virol (1996) 1.69
The WW module competes with the SH3 domain? Trends Biochem Sci (1996) 1.66
Human immunodeficiency virus type 1 Vif protein binds to the Pr55Gag precursor. J Virol (1997) 1.55
A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat. Proc Natl Acad Sci U S A (1990) 1.55
Vif and the p55(Gag) polyprotein of human immunodeficiency virus type 1 are present in colocalizing membrane-free cytoplasmic complexes. J Virol (1999) 1.44
Phosphorylation of Vif and its role in HIV-1 replication. J Biol Chem (1996) 1.44
Cysteine residues in the Vif protein of human immunodeficiency virus type 1 are essential for viral infectivity. J Virol (1994) 1.42
Phenotypically Vif- human immunodeficiency virus type 1 is produced by chronically infected restrictive cells. J Virol (1997) 1.38
Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains. J Virol (1995) 1.36
Analysis of vif-defective human immunodeficiency virus type 1 (HIV-1) virions synthesized in 'non-permissive' T lymphoid cells stably infected with selectable HIV-1. J Gen Virol (1997) 1.27
In vivo genetic variability of the HIV-1 vif gene. Virology (1994) 1.18
Virion incorporation of human immunodeficiency virus type-1 Vif is determined by intracellular expression level and may not be necessary for function. Virology (1998) 1.01
Unimpaired function of a naturally occurring C terminally truncated vif gene product of human immunodeficiency virus type 1. J Gen Virol (1996) 0.87
A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med (2001) 16.32
Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol (2000) 8.62
Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro Surveill (2012) 4.96
Pathogenesis of influenza A (H5N1) virus infection in a primate model. J Virol (2001) 4.90
The HIV-1 Rev protein. Annu Rev Microbiol (1998) 4.78
Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes. J Exp Med (1991) 4.56
Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci U S A (1997) 4.07
Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat Med (1998) 3.84
Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science (1993) 3.62
Nef protein of human immunodeficiency virus type 1: evidence against its role as a transcriptional inhibitor. Proc Natl Acad Sci U S A (1989) 3.43
The HIV-1 Rev trans-activator shuttles between the nucleus and the cytoplasm. Genes Dev (1994) 3.34
Functional replacement of the HIV-1 rev protein by the HTLV-1 rex protein. Nature (1988) 3.31
HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science (1998) 3.28
The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J Virol (1996) 3.22
Comparative analysis of the HTLV-I Rex and HIV-1 Rev trans-regulatory proteins and their RNA response elements. Genes Dev (1989) 3.09
Reverse transcriptase activity and Ty RNA are associated with virus-like particles in yeast. Nature (1986) 3.07
Mutational analysis of the conserved basic domain of human immunodeficiency virus tat protein. J Virol (1989) 2.89
Influenza B virus in seals. Science (2000) 2.70
The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells. J Virol (1997) 2.39
Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes. J Virol (1995) 2.35
HIV-1 infection requires a functional integrase NLS. Mol Cell (2001) 2.26
Antigenic drift in the influenza A virus (H3N2) nucleoprotein and escape from recognition by cytotoxic T lymphocytes. J Virol (2000) 2.25
The VP16 transcription activation domain is functional when targeted to a promoter-proximal RNA sequence. Genes Dev (1992) 2.24
Structure-function analyses of the HTLV-I Rex and HIV-1 Rev RNA response elements: insights into the mechanism of Rex and Rev action. Genes Dev (1990) 2.24
Unusual polymorphisms in human immunodeficiency virus type 1 associated with nonprogressive infection. J Virol (2000) 2.04
Identification of a high-affinity RNA-binding site for the human immunodeficiency virus type 1 Rev protein. Proc Natl Acad Sci U S A (1992) 1.96
Importin beta can mediate the nuclear import of an arginine-rich nuclear localization signal in the absence of importin alpha. Mol Cell Biol (1999) 1.91
A highly conserved RNA folding region coincident with the Rev response element of primate immunodeficiency viruses. Nucleic Acids Res (1990) 1.90
Amphibian transcription factor IIIA proteins contain a sequence element functionally equivalent to the nuclear export signal of human immunodeficiency virus type 1 Rev. Proc Natl Acad Sci U S A (1996) 1.87
Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individual. J Virol (1991) 1.83
Secreted placental alkaline phosphatase as a eukaryotic reporter gene. Methods Enzymol (1992) 1.80
Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J Virol (1996) 1.76
Changing virus-host interactions in the course of HIV-1 infection. Immunol Rev (1994) 1.73
Interaction of the human immunodeficiency virus type 1 Vpr protein with the nuclear pore complex. J Virol (1998) 1.70
The HIV-1 Rev protein: prototype of a novel class of eukaryotic post-transcriptional regulators. Trends Biochem Sci (1991) 1.67
Nuclear import of human immunodeficiency virus type-1 preintegration complexes. Adv Virus Res (1999) 1.63
Phosphorylation of the rev gene product of human immunodeficiency virus type 1. J Virol (1988) 1.61
Analysis of the junctions between human immunodeficiency virus type 1 proviral DNA and human DNA. J Virol (1990) 1.54
Influenza virus: a master of metamorphosis. J Infect (2000) 1.50
Differential regulation of CXCR4 and CCR5 endocytosis. J Cell Sci (1998) 1.49
In vivo attenuation of simian immunodeficiency virus by disruption of a tyrosine-dependent sorting signal in the envelope glycoprotein cytoplasmic tail. J Virol (2001) 1.45
Vif and the p55(Gag) polyprotein of human immunodeficiency virus type 1 are present in colocalizing membrane-free cytoplasmic complexes. J Virol (1999) 1.44
[Influenza pandemics: past and future]. Ned Tijdschr Geneeskd (1999) 1.42
The human T-cell leukemia virus type 1 posttranscriptional trans-activator Rex contains a nuclear export signal. J Virol (1996) 1.42
Conserved functional organization of the human immunodeficiency virus type 1 and visna virus Rev proteins. J Virol (1991) 1.41
Productive HIV-1 infection of macrophages restricted to the cell fraction with proliferative capacity. EMBO J (1994) 1.41
Functional analysis of the Tat trans activator of human immunodeficiency virus type 2. J Virol (1989) 1.40
Guiding outbreak management by the use of influenza A(H7Nx) virus sequence analysis. Euro Surveill (2013) 1.38
A comparison of rapid point-of-care tests for the detection of avian influenza A(H7N9) virus, 2013. Euro Surveill (2013) 1.35
Expression strategies of the yeast retrotransposon Ty: a short sequence directs ribosomal frameshifting. Nucleic Acids Res (1986) 1.33
Wild bird surveillance around outbreaks of highly pathogenic avian influenza A(H5N8) virus in the Netherlands, 2014, within the context of global flyways. Euro Surveill (2015) 1.31
Antigenic and genetic characterization of swine influenza A (H1N1) viruses isolated from pneumonia patients in The Netherlands. Virology (2001) 1.30
Complete nucleotide sequence of a mouse VL30 retro-element. Mol Cell Biol (1988) 1.23
Lessons from the cat: feline immunodeficiency virus as a tool to develop intervention strategies against human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (1998) 1.19
Sequence requirements for Rev multimerization in vivo. Virology (1994) 1.18
Derivation of a biologically contained replication system for human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1992) 1.18
Biochemical analyses of the interactions between human immunodeficiency virus type 1 Vpr and p6(Gag). J Virol (2001) 1.14
Determinants of syncytium formation in microglia by human immunodeficiency virus type 1: role of the V1/V2 domains. J Virol (2000) 1.14
Intracellular trafficking of HIV-1 cores: journey to the center of the cell. Curr Top Microbiol Immunol (2003) 1.09
Biological phenotype of HIV type 2 isolates correlates with V3 genotype. AIDS Res Hum Retroviruses (1996) 1.04
Inhibition of influenza virus replication by nitric oxide. J Virol (1999) 1.04
Early replication steps but not cell type-specific signalling of the viral long terminal repeat determine HIV-1 monocytotropism. AIDS Res Hum Retroviruses (1993) 1.02
Rev-mediated nuclear export of RNA is dominant over nuclear retention and is coupled to the Ran-GTPase cycle. Nucleic Acids Res (1999) 1.01
Virion incorporation of human immunodeficiency virus type-1 Vif is determined by intracellular expression level and may not be necessary for function. Virology (1998) 1.01
Scanning mutagenesis of the arginine-rich region of the human immunodeficiency virus type 1 Rev trans activator. J Virol (1994) 0.93
Antigen processing for MHC class I restricted presentation of exogenous influenza A virus nucleoprotein by B-lymphoblastoid cells. Clin Exp Immunol (2001) 0.93
Antigenic and molecular heterogeneity in recent swine influenza A(H1N1) virus isolates with possible implications for vaccination policy. Vaccine (2001) 0.91
Envelope V2 configuration and HIV-1 phenotype: clarification. Science (1995) 0.90
[The 2002/2003 influenza season in the Netherlands and the vaccine composition for the 2003/2004 season]. Ned Tijdschr Geneeskd (2003) 0.90
Gold nanoparticle-mediated gene delivery induces widespread changes in the expression of innate immunity genes. Gene Ther (2011) 0.85
Completion of nucleotide sequences of non-syncytium-inducing and syncytium-inducing HIV type 1 variants isolated from the same patient. AIDS Res Hum Retroviruses (1995) 0.83
[2000/01 influenza season and the vaccine composition for the season 2001/'02]. Ned Tijdschr Geneeskd (2001) 0.83
Nuclear export of human immunodeficiency virus type 1 Vpr is not required for virion packaging. J Virol (2001) 0.82
The genetic organization of the yeast Ty element. J Cell Sci Suppl (1987) 0.80
Syncytium-inducing HIV-1 variants replicate equally well in all types of T-helper cell clones. AIDS (1996) 0.79
Adhesion molecule expression in the bovine mammary gland. Vet Immunol Immunopathol (2006) 0.78
[Influenza season 1999/2000 and vaccine composition for the season 2000/01]. Ned Tijdschr Geneeskd (2000) 0.78
Human placental alkaline phosphatase as a marker for gene expression. Methods Mol Biol (1997) 0.78
[Influenza season 1998/99; composition of vaccine for 1999/2000]. Ned Tijdschr Geneeskd (1999) 0.78
Rudimentary phosvitin domain in a minor chicken vitellogenin gene. Biochemistry (1989) 0.77
The American Dietetic Association--1966-67. President's report to members. J Am Diet Assoc (1967) 0.75
A half century of progress. J Am Diet Assoc (1967) 0.75
Effects on adhesion molecule expression and lymphocytes in the bovine mammary gland following intra-mammary immunisation. Vet Immunol Immunopathol (2009) 0.75
[Neuraminidase inhibitors oseltamivir and zanamivir: new means of defence against influenza]. Ned Tijdschr Geneeskd (2004) 0.75